Rafael Holdings (RFL) Non Operating Interest Expenses (2021 - 2026)
Rafael Holdings' (RFL) quarterly Non Operating Interest Expenses came in at $6000.0 in Q2 2026, down 96.36% year-over-year from $165000.0 in Q2 2025, and down 96.27% quarter-over-quarter from $161000.0 in Q1 2026.
Analysis
Rafael Holdings (RFL) Non Operating Interest Expenses (2021 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported Non Operating Interest Expenses for 6 consecutive years, with $6000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non Operating Interest Expenses fell 96.36% year-over-year to $6000.0 in Q2 2026; TTM through Apr 2026 was $495000.0, a 24.2% decrease from a year earlier, with the FY2025 full-year figure at $658000.0, up 165.32% from the prior year.
- Non Operating Interest Expenses was $6000.0 for Q2 2026 at Rafael Holdings, down from $161000.0 in the prior quarter.
- Over five years, Non Operating Interest Expenses peaked at $168000.0 in Q3 2025 and troughed at -$13000.0 in Q3 2022.
- A 5-year average of $105857.1 and a median of $123500.0 in 2022 frame the typical range for Non Operating Interest Expenses.
- Across the five-year window, Non Operating Interest Expenses tumbled 122.03% in 2022 and jumped 769.23% in 2023, its largest moves.
- Over 5 years, Non Operating Interest Expenses stood at $87000.0 in 2022, then changed by 0.0% to $87000.0 in 2023, then surged by 86.21% to $162000.0 in 2024, then retreated by 1.23% to $160000.0 in 2025, then slumped by 96.25% to $6000.0 in 2026.
- The last three Non Operating Interest Expenses figures came in at $6000.0 (Q2 2026), $161000.0 (Q1 2026), and $160000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | 6,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | 6,000.00 |
| Jan 31, 2026 | 161,000.00 |
| Oct 31, 2025 | 160,000.00 |
| Jul 31, 2025 | 168,000.00 |
| Apr 30, 2025 | 165,000.00 |
| Jan 31, 2025 | 163,000.00 |
| Oct 31, 2024 | 162,000.00 |
| Jul 31, 2024 | 163,000.00 |
| Apr 30, 2024 | 85,000.00 |
| Jul 31, 2023 | 87,000.00 |
| Oct 31, 2022 | 87,000.00 |
| Jul 31, 2022 | -13,000.00 |
| Apr 30, 2022 | 1,000.00 |
| Jan 31, 2022 | 87,000.00 |
| Oct 31, 2021 | 271,000.00 |
| Jul 31, 2021 | 59,000.00 |
| Apr 30, 2021 | 3,000.00 |